TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02062203
Drug: AKB-6548 (therapeutic dose)
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of AKB-6548 at a therapeutic dose level
Study: NCT02062203
Drug: AKB-6548 (supratherapeutic dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of AKB-6548 at a supratherapeutic dose level
Study: NCT02062203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of placebo
Study: NCT01704703
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
Study: NCT00793793
Drug: BI201335
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
Study: NCT04151849
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with GLP-1 agonist for up to 1 year.
Study: NCT02881528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
Study: NCT00793793
Drug: BI201335
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
Study: NCT00793793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00979849
Drug: AZD8683
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
Study: NCT00979849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for nebulisation, inhaled
Study: NCT00127309
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03562416
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00106574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv every 4 weeks
Study: NCT01286584
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
Study: NCT02770521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT02770521
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT00238368
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00238368
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02159807
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 micrograms routinely administered in combination in the spinal anesthetic
Study: NCT01350115
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: supplied as 100 mg capsules
Study: NCT01350115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: supplied in capsules
Study: NCT01552902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dosing in the AM for 6 weeks
Study: NCT03645304
Drug: 0.9% saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
Study: NCT01113034
Drug: DAS181 dry powder, formulation F02
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg delivered dose DAS181 in clear HPMC #3 Capsules
Study: NCT01113034
Drug: Respitose ML006 (DMV-Fonterra)
Normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL SPRAY [doTERRA sun]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate
Study: NCT00006268
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00783081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for 26 weeks.
Study: NCT04031872
Drug: LY3200882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with LY3200882 and capecitabine
Study: NCT01179061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
Study: NCT02479789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03804671
Drug: BI 730357 mixed with [C-14] BI 730357 BS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose
Study: NCT01571063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tbl. p.o.
Study: NCT03143998
Drug: MK-5172A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Study: NCT00556179
Drug: Lactoserum (Dermacyd Femina®)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day during three months
Study: NCT02571660
Drug: GINA treatment fot asthma +vit.D low supplementation dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
Study: NCT02571660
Drug: GINA treatment fot asthma +vit.D high supplementation dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
Study: NCT01066351
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
Study: NCT02194322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01688739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection or intravenous injection
Study: NCT00996801
Drug: MK-5442
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
Study: NCT00996801
Drug: Placebo to MK-5442
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MK-5442 taken orally, once-daily, for 12 months
Study: NCT00996801
Drug: Placebo to Alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to alendronate once-weekly for 12 months
Study: NCT02335632
Drug: Probiotics (Lacidofil®)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
Study: NCT02335632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For probiotics
Study: NCT01973608
Drug: MSB0010445 (0.3 milligram per kilogram [mg/kg])
Normalized name: ALLOGENIC ADIPOSE DERIVED MESENCHYMAL STEM CELLS (MSCS) EXOSOMES 15 mg in 3 mL TOPICAL POWDER, FOR SOLUTION [Biogram Anti Hair Loss Ampoule]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
Study: NCT01973608
Drug: MSB0010445 (1.0 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Study: NCT01973608
Drug: MSB0010445 (1.8 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Study: NCT01973608
Drug: MSB0010445 (2.4 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Study: NCT03917069
Drug: Chemotherapeutic Combinations
Normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
Study: NCT03917069
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
Study: NCT00002514
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002514
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002514
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002514
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02408692
Drug: ECx1
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.
Study: NCT03913845
Drug: lidocaine with epinephrine
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
Study: NCT03913845
Drug: Normal saline with epinephrine
Normalized name: Sensorcaine with Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
Study: NCT01976858
Drug: PEX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: A injection administered subcutaneously
Study: NCT04790487
Drug: CPM
Normalized name: CPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
Study: NCT04790487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT04792333
Drug: firibastat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 500 mg administration on Day 1
Study: NCT00673881
Drug: choline fenofibrate
Normalized name: Choline Fenofibrate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 135 mg choline fenofibrate daily(oral, capsule)
Study: NCT02642146
Drug: Calcium Channel Blockers
Normalized name: CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02642146
Drug: Phosphodiesterase Inhibitors
Normalized name: Phosphodiesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02642146
Drug: Endothelin receptor blocker
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02642146
Drug: Prostanoids
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02642146
Drug: Other vasodilator
Normalized name: Other vasodilators used in cardiac diseases
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03545997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
Study: NCT02408692
Drug: ECx2
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
Study: NCT03283150
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
Study: NCT00360347
Drug: C.E.R.A.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542191
Drug: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
Study: NCT04072107
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
Study: NCT00539617
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV once every 2 weeks for 16 weeks
Study: NCT05918627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule; Route of administration: oral
Study: NCT03772418
Drug: Cream Base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
Study: NCT01616485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules for TA-1790 100 mg capsules
Study: NCT01743404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Inflaminat 500 mg tablet
Study: NCT00693004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000120
Drug: Erythromycin Ointment
Normalized name: Erythromycin Ointment
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01533922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching tiotropium + olodaterol FDC
Study: NCT00784732
Drug: QAV680
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00675896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
Study: NCT04292990
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
Study: NCT03713190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A substance without specific pharmacology principles
Study: NCT03242252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral
Study: NCT00993499
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
Study: NCT02192229
Drug: Placebo (to mimic Biodal 50,000 IU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
Study: NCT01020708
Drug: ALTH12-1:4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
Study: NCT01020708
Drug: ALTH12-2:4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
Study: NCT01051206
Drug: 6% hydroxyethyl Stach 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
Study: NCT00334282
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo (800 mg tablet) once daily
Study: NCT03759964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of IV isotonic serum saline at day 1 following surgery
Study: NCT01281228
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion
Study: NCT04049110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
Study: NCT00162266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Study: NCT00764907
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV during reinduction
Study: NCT00764907
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV during reinduction
Study: NCT00764907
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV during reinduction
Study: NCT00764907
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally during reinduction
Study: NCT00764907
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally during reinduction
Study: NCT02270827
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous medication
Study: NCT00620438
Drug: Lumefantrine-artemether and rifampicin
Normalized name: artemether and lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
Study: NCT01821456
Drug: Antiinfectives
Normalized name: Antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: To analyze to efficacy of (novel) drug therapies
Study: NCT00012558
Drug: inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04336891
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
Study: NCT04336891
Drug: Estradiol ovules
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
Study: NCT04336891
Drug: Testosterone gel + Estradiol ovules
Normalized name: estradiol / testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months